Fig. 2From: Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastomaMR images(all T1-weighted images)at baseline, at the time of optimal efficacy and at the time of progression in five patients who achieved partial remission (MR at the time of relapse was not recorded in three of these patients due to loss to follow-up)Back to article page